文献速递淋巴瘤

侵袭性B细胞淋巴瘤CAR-T治疗失败后检查点抑制的疗效:来自美国15家机构的结果

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
PubMed 文献 · Blood Adv · 2023-01-01

这项回顾性研究纳入美国15家学术中心的96例CAR-T失败后接受检查点抑制剂(CPI)治疗的侵袭性B细胞淋巴瘤患者,总缓解率19%、完全缓解率10%,中位无进展生存期54天、总生存期159天,仅5%获得持久缓解,作者认为CPI对多数CAR-T后患者不是有效挽救策略。

要点

  • CAR-T失败后CPI治疗总缓解率19%、完全缓解率10%,仅5%获持久缓解。
  • 中位无进展生存期54天、总生存期159天,83%患者死亡,多因疾病进展。
  • CAR-T后晚期(>180天)复发者无进展生存期128天 vs 早期(≤180天)51天,总生存期387天 vs 131天。

核心结论

  • 作者结论认为CPI对多数CAR-T后患者不是有效挽救策略,需要替代方法改善CAR-T后结局。

研究设计与样本

  • 回顾性评估美国15家学术中心96例CAR-T失败后接受CPI治疗的侵袭性B细胞淋巴瘤患者的临床结局。
  • 53%为弥漫大B细胞淋巴瘤,53%接受阿基仑赛治疗,83%在CAR-T后早期(≤180天)复发,49%接受帕博利珠单抗、43%接受纳武利尤单抗。

主要发现

  • CPI治疗总缓解率19%、完全缓解率10%,中位缓解持续时间221天。
  • 中位无进展生存期54天、中位总生存期159天。
  • 原发纵隔B细胞淋巴瘤患者CPI结局显著改善。
  • CAR-T后晚期(>180天)复发者无进展生存期128天 vs 早期(≤180天)51天,总生存期387天 vs 131天,均显著更长。
  • 19%接受CPI治疗的患者发生≥3级不良事件;83%患者死亡,常见原因为疾病进展;仅5%对CPI治疗获得持久缓解。

临床怎么用

  • 作者认为CPI对多数CAR-T后患者不是有效挽救策略,需要替代方法改善CAR-T后结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (>180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post-CAR-T outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Major A, Yu J, Shukla N, et al. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023. PMID: 37026796. doi:10.1182/bloodadvances.2023010016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。